Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: The first US phase 2 experience

Pancreas

Volumn 43, Issue 4, 2014, Pages 518-525

  Delpassand, Ebrahim S ^a,b   Samarghandi, Amin ^a   Zamanian, Sara ^b   Wolin, Edward M ^c   Hamiditabar, Mohammadali ^a   Espenan, Gregory D ^d   Erion, Jack L ^e   O'Dorisio, Thomas M ^f   Kvols, Larry K ^g   Simon, Jaime ^h   Wolfangel, Robert ⁱ   Camp, Arthur ^j   Krenning, Eric P ^k   Mojtahedi, Alireza ^b  

^a Excel Diagnostics and Nuclear Oncology Center   (United States)

^b RadioMedix Inc   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d Physics Services Incorporated   (United States)

^e BioSynthema Inc   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h IsoTherapeutics Group   (United States)

ⁱ Certus International   (United States)

^j Iso tex Diagnostics Inc   (United States)

^k ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Neuroendocrine tumors; Peptide receptor radionuclide therapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOTATATE LU 177; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; FLUORODEOXYGLUCOSE F 18; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; LIVER DISEASE; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REPEATED DRUG DOSE; SKIN REDNESS; TREATMENT RESPONSE; UNITED STATES; ANALOGS AND DERIVATIVES; CANCER GRADING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM NEOPLASMS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODAL IMAGING; NEUROENDOCRINE TUMORS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RADIATION DOSE FRACTIONATION; SECONDARY; TIME; TREATMENT OUTCOME;

ADULT; AGED; DIGESTIVE SYSTEM NEOPLASMS; DISEASE PROGRESSION; DOSE FRACTIONATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TEXAS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84898487114     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000113     Document Type: Article

References (34)

1. Raut CP, Kulke MH, Glickman JN, et al. Carcinoid tumors. Curr Probl Surg. 2006;43:383-450.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after carcinoid : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
3. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(suppl 1):3-7.
4. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;8:1351-1355.
5. Sowa-Staszczak A, Pach D, Chrzan R, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011;38:1669-1674.
6. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
7. Krausz Y, Bar-Ziv J, de Jong RB, et al. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol. 1998;93:66-70.
8. 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol. 2011;13:583-593.
9. 111In-DTPA-D-Phe1]-octreotide: a case history. Ann N Y Acad Sci. 1994;733:496-506.
10. Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 2008;23:292-300.
11. Delpassand ES, Samarghandi A, Mourtada JS, et al. Long-term survival, toxicity profile, and role of F-18 FDG PET/CT scan in patients with progressive neuroendocrine tumors following peptide receptor radionuclide therapy with high activity In-111 pentetreotide. Theranostics. 2012;2:472-480.
12. Krenning EP, de Jong M, Kooij PP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(suppl 2):S23-S29.
13. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941-945.
14. 90Y-DOTATOC. J Nucl Med. 2002;43:610-616.
15. Waldherr C, Schumacher T, Maecke HR, et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med. 2002;29(suppl):S100.
16. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
17. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
18. Nguyen C, Faraggi M, Giraudet AL, et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med. 2004;45:1660-1668.
19. Gehan, E.A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961;13:346-353.
20. Lee YJ, Catane R, Rozencweig M, et al. Analysis and interpretation of response rates for anticancer drugs. Cancer Treat Rep. 1979;63(11-12):1713-1720.
21. 177Lu-DOTA0, Tyr3] octreotate. J Clin Oncol. 2004;22:2724-2729.
22. 177Lu-DOTA0, Tyr3] octreotate. J Nucl Med. 2011;52: 1361-1368.
23. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302-311.
24. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
25. van Vliet EI, Teunissen JJ, Kam BL, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology. 2013;97:74-85.
26. 111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28:1319-1325.
27. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion. 2000;62(suppl 1):84-91.
28. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54:61-67.
29. Anthony LB,Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123-132.
30. Teunissen JJ, Kwekkeboom DJ, Valkema R, et al. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011;18(suppl 1):S27-S51.
31. Van Essen M, Krenning EP, De Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor-positive tumours. Acta Oncol. 2007;46:723-734.
32. 177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
33. Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:173-185, ix.
34. Salavati A, Prasad V, Schneider CP, et al. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med. 2012;26:365-369.